Suppr超能文献

抗菌剂2,5-双(4-脒基苯基)呋喃通过其甲脒基前药提高跨Caco-2细胞单层的通透性。

Enhanced permeability of the antimicrobial agent 2,5-bis(4-amidinophenyl)furan across Caco-2 cell monolayers via its methylamidoidme prodrug.

作者信息

Zhou Liao, Lee Kiho, Thakker Dhiren R, Boykin David W, Tidwell Richard R, Hall James E

机构信息

Division of Medicinal Chemistry and Natural Products, Georgia State University. Atlanta, Georgia 30303, USA.

出版信息

Pharm Res. 2002 Nov;19(11):1689-95. doi: 10.1023/a:1020957430400.

Abstract

PURPOSE

DB75 [2.5-bis(4-amidinophenyl)furan] is a promising antimicrobial agent although it has poor oral potency. In contrast, its novel prodrug, 2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime (DB289). has excellent oral potency. The mechanisms of transport of DB289 and DB75 across intestinal epithelium have been investigated in these studies to understand differences in their oral potency.

METHODS

Caco-2 cell monolayers were used as an in vitro model to examine the mechanisms of transport of DB289 and DB75. Samples collected from the transport studies were quantified using high-performance liquid chromatography with ultraviolet and fluorescence detection.

RESULTS

A low permeability coefficient (3.8 x 10(-7) cm/s for transport in apical [AP] to basolateral [BL] direction) and high sensitivity to extracellular Ca2+ suggest that AP to BL transport of DB75 across Caco-2 cell monolayers occurs predominantly via a paracellular route. DB289 has an 85-fold higher transport rate (322.0 x 10(-7) cm/s for transport in the AP to BL direction) across Caco-2 monolayers than that of DB75. This, with its insensitivity to extracellular Ca2+ indicates that AP to BL transport of DB289 across Caco-2 cell monolayers occurs predominantly via a transcellular route.

CONCLUSIONS

DB75 is transported across Caco-2 cell monolayers predominantly via paracellular pathways, whereas the prodrug DB289 is transported via transcellular pathways. This could account for the much higher oral activity of DB289 over DB75.

摘要

目的

DB75[2,5-双(4-脒基苯基)呋喃]是一种有前景的抗菌剂,尽管其口服效力较差。相比之下,其新型前药2,5-双(4-脒基苯基)呋喃-双-O-甲基偕胺肟(DB289)具有出色的口服效力。在这些研究中,对DB289和DB75跨肠上皮细胞的转运机制进行了研究,以了解它们口服效力差异的原因。

方法

使用Caco-2细胞单层作为体外模型来研究DB289和DB75的转运机制。通过高效液相色谱结合紫外和荧光检测对转运研究中收集的样品进行定量分析。

结果

低渗透系数(从顶侧[AP]到基底外侧[BL]方向转运时为3.8×10(-7)cm/s)以及对细胞外Ca2+的高敏感性表明,DB75从AP到BL方向跨Caco-2细胞单层的转运主要通过细胞旁途径进行。DB289跨Caco-2单层的转运速率比DB75高85倍(从AP到BL方向转运时为322.0×10(-7)cm/s)。这一点及其对细胞外Ca2+的不敏感性表明,DB289从AP到BL方向跨Caco-2细胞单层的转运主要通过跨细胞途径进行。

结论

DB75主要通过细胞旁途径跨Caco-2细胞单层转运,而前药DB289则通过跨细胞途径转运。这可以解释DB289比DB75具有更高口服活性的原因。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验